My colleague Vikas Dandekar, Pharmasianews bureau chief in India, recently tweeted the following comments from GSK CEO Andrew Witty (at an investor call). "I'm not paying 37 times earnings for an Indian company, I am just not." "We are going to walk away from opportunities that go out of our price range, and where we … Continue reading GSK’s Witty does some tough talk on India M&A
Apothecurry 